Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04736173 2026-03-30

ARC-10

Phase 2 Active not recruiting

169 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05329766 2026-03-30

EDGE-Gastric

Phase 2 Active not recruiting

332 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Phase 2 Active not recruiting

70 enrolled

Genitourinary

Urothelial Bladder Carcinoma

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Phase 2 Active not recruiting

10 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06727565 2026-03-02

VELOCITY-HNSCC

Phase 2 Active not recruiting

100 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

1,021 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

Phase 1 Active not recruiting

182 enrolled

Other solid neoplasm

Solid Tumor

NCT04791839 2025-11-05

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05886634 2025-10-20

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Phase 2 Active not recruiting

16 enrolled

Sarcoma

Liposarcoma, Sarcoma

NCT05676931 2025-10-02

EDGE-Lung

Phase 2 Active not recruiting

400 enrolled

Thoracic

Advanced Non-Small Cell Lung Cancer

NCT05724563 2025-05-21

Domvanalimab and Zimberelimab in Advanced Liver Cancers

Phase 2 Active not recruiting

58 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

Clinical Trials

AB154 Combined With AB122 for Recurrent Glioblastoma

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

STAR-221

ARC-8

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

ARC-25

ARC-10

EDGE-Gastric

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

VELOCITY-HNSCC

STAR-121

Study of GS-4528 in Adults With Solid Tumors

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

EDGE-Lung

Domvanalimab and Zimberelimab in Advanced Liver Cancers